Stem cells in liver failure

Russo, Francesco Paolo; Parola, Maurizio

doi:10.1016/j.bpg.2012.01.001

Cited by 31 publications

(18 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identification of the stem cells can be made by immunohistochemical staining of the markers expressed during early stages (e.g., SSEA-1) or gene products (e.g., Oct4, alkaline phosphatase, etc.) (1,15,30). In our study, elevated SSEA-1 levels in the BDL group were reversed by all treatment regimens, suggesting the inhibitory action of the treatments on stem cell-induced hepatic fibrosis.…”

Section: Discussionsupporting

confidence: 53%

Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells

Alaca

Özbeyli²,

Uslu³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells

Alaca

Özbeyli²,

Uslu³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

“…t is well documented in humans, as well as in experimental animals that the stem cell compartment can restore the liver parenchyma after extensive damage [1]. Unfortunately this process is often not efficient enough.…”

mentioning

confidence: 99%

Expansion of Hepatic Stem Cell Compartment Boosts Liver Regeneration

Papp

Rókusz

Dezső

et al. 2014

Stem Cells and Development

View full text Add to dashboard Cite

The hepatic stem cells reside periportally forming the canals of Hering in normal liver. They can be identified by their unique immunophenotype in rat. The oval cells, the progenies of stem cells invade deep the liver parenchyma after activation and differentiate into focally arranged small-and eventually trabecularly ordered regular hepatocytes. We have observed that upon the completion of intense oval cell reactions narrow ductular structures are present in the parenchyma, we propose to call them parenchymal ductules. These parenchymal ductules have the same immunophenotype [cytokeratin (CK)7 -/CK19 + /alpha-fetoprotein (AFP) -/delta-like protein (DLK) -] as the resting stem cells of the canals of Hering, but different from them reside scattered in the parenchyma. In our present experiments, we have investigated in an in vivo functional assay if the presence of these parenchymal ductules has any impact on a progenitor cell driven regeneration process. Parenchymal ductules were induced either by an established model of oval cell induction consisting of the administration of necrogenic dose of carbontetrachloride to 2-acetaminofluorene pretreated rats (AAF/CCl 4 ) or a large necrogenic dose of diethylnitrosamine (DEN). The oval cells expanded faster and the foci evolved earlier after repeated injury in the livers with preexistent parenchymal ductules. When the animals were left to survive for one more year increased liver tumor formation was observed exclusively in the DEN treated rats. Thus, repeated oval cell reactions are not necessarily carcinogenic. We conclude that the expansion of hepatic stem cell compartment conceptually can be used to facilitate liver regeneration without an increased risk of tumorigenesis.

show abstract

“…[36] Most studies reported loss or reduction in the effect after the first 3 months of infusion. In this case, it seems reasonable to suggest repeated infusions in future studies to see if that will result in a more long term and durable response.…”

Section: Clinical Studiesmentioning

confidence: 99%

Autologous bone marrow-derived cells in the treatment of liver disease patients

AlAhmari

Alshenaifi

Alanazi

et al. 2015

Saudi J Gastroenterol

View full text Add to dashboard Cite

Liver transplantation is universally accepted as a “cure” procedure, and yet is not universally applicable for the treatment of end-stage liver diseases (ESLD) because of the shortage of donors, operative complications, risk of rejection, and high cost. Bioartificial liver device is an option to temporarily improve the liver function and to bridge the patients to liver transplantation. However, bioartificial liver device has many problems in clinical application, such as hepatocyte allograft rejection and maintenance of hepatocyte viability and function. Another therapeutic option is stem cell transplantation. There are two broad types of stem cells: Embryonic stem cells and adult stem cells. The latter are sourced from bone marrow (BM), adipose tissue, and blood. This review will concentrate on BM-derived cells. BM-derived cell transplantation, although not ideal, is theoretically an optimal modality for the treatment of ESLD. Autologous BM-derived cells have no graft rejection, have the capability of regeneration and self-renewal, and are multipotent stem cells that can differentiate into a variety of cell types which include hepatocytes. The pathway from BM-derived cell to hepatocyte is well documented. The present review summarizes the delivery routes of BM-derived cells to the liver, the evidences of engraftment of BM-derived cells in the liver, and the possible mechanisms of BM-derived cells in liver repair and regeneration, and finally, updates the clinical applications.

show abstract

Stem cells in liver failure

Cited by 31 publications

References 96 publications

Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells

Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells

Expansion of Hepatic Stem Cell Compartment Boosts Liver Regeneration

Autologous bone marrow-derived cells in the treatment of liver disease patients

Contact Info

Product

Resources

About